EXECUTIVE SUMMARY

 

1) PLASMA COLLECTIONS

1.1)  Plasma Collections

1.2)  Safety Measures for Source Plasma

1.3)  Major Plasma Collection Organizations

1.3.1)  Independent Plasma Collection Companies

1.3.2)  Plasma Collection Facilities owned by the Fractionators

1.3.3)  Plasma Collected by the Blood Banking Sector

1.3.4)  The Plasma Supply and Demand Cycle

1.3.5)  International Plasma Transfers

1.3.6)  Plasma Prices

 

2) PLASMA FRACTIONATION

2.1)  Processing Capacity and Throughput

2.2)  Fractionation Plant Expansion

2.3)  Fractionation Production Cycle

2.4)  Fractionation Standards

2.5)  Production Yields

 

3) MARKET OVERVIEW

3.1)  The Plasma Proteins Market by Product

3.1.1)  Polyvalent Intravenous Immune Globulin (IVIG)

and Subcutaneous

3.1.2)  Albumin and Plasma Protein Fraction (PPF)

3.1.3)  Factor VIII

3.1.4)  von Willebrand Factor

3.1.5)  Factor IX

3.1.6)  Prothrombin Complex Concentrates (PCC)

3.1.7)  Inhibitor Products (Factor VIII/IX Bypassing Agents)

3.1.8)  Fibrinogen

3.1.9)  Factor XIII

3.1.10)  Alpha 1 Antitrypsin

3.1.11)  C-1 Esterase Inhibitor

3.1.12)  Antithrombin III

3.1.13)  Fibrin Sealant

3.1.14)  Thrombin

3.1.15)  Protein C

3.1.16)  Hyperimmune Globulin Products

3.2)  Pricing Trends

3.3)  Product Mix

3.4)  The Plasma Fractions Market by Company

3.5)  Historical Development

3.6)  Products Approvals January 2007 to December 2014

3.7)  Products Approvals January 2015 to June 2017

 

4) IMMUNE GLOBULIN MARKET

4.1)  Intramuscular Polyvalent Immune Globulin Market and

Hyperimmune Globulin Products

4.1.1)  Polyvalent Intramuscular Immune Globulin

4.1.2)  Tetanus Immune Globulin

4.1.3)  Rabies Immune Globulin

4.1.4)   Hepatitis B Immune Globulin

4.1.5)  Rho(D) Immune Globulin

4.1.6)  Cytomegalovirus Intravenous Immune Globulin

4.1.7)  Varicella-Zoster Immune Globulin

4.1.8)  Hepatitis C Immune Globulin

4.1.9)  Anthrax Immune Globulin

4.1.10)  Other Immune Globulin

4.2)  Polyvalent Intravenous Immune Globulin Market (IVIG)

4.2.1) Polyvalent Intravenous Immune Globulin (IVIG) History

4.2.2)  Subcutaneous Immune Globulin (SCIG)

4.2.3)  Clinical Use of IVIG/SCIG

4.2.4)  IVIG and Alzheimer’s

4.2.5)  Market Development

4.2.6)  Historical Developments

4.2.7)  Role of Patients Organizations

4.2.8)  Results by Company

4.2.9)  IV/SCIG Pricing and Reimbursement

4.2.10)  IV/SCIG Distribution

 

5)  ALBUMIN MARKET

5.1)  History of Albumin

5.2)  Clinical Use of Albumin

5.3)  Colloids vs. Crystalloids

5.4)  Albumin Safety Issues

5.5)  Non-Therapeutic Use of Albumin and Recombinant Albumin

5.6)  Therapeutic Apheresis Market

5.7)  Market Development

5.7.1)  Historical Development

5.7.2)  Current Market Development

5.7.3)  Current Albumin Products

5.7.4)  5% verses 25% Albumin in the US

5.8) Albumin Research Studies

5.8.1) Alzheimer’s disease: A study to Evaluate Albumin and

Immunoglobulin in Alzheimer’s Disease (AMBAR)

5.8.2)  Severe Sepsis and Septic Shock

5.8.3) Volume Replacement with

Albumin Sepsis (ALBIOS Study) Italy

5.8.4) Albumin and Cirrhosis bacterial infection

5.8.5) Albumin for the treatment of Ascites in Patients

with Hepatic Cirrhosis

5.8.6) Use of Hetastarch vs Albumin in Cardiac Surgery

 

6) HEMOPHILIA CARE MARKET

6.1)  Introduction

6.2)  Historical Development

6.3)  Hemophilia Patient Population

6.4)  Hemophilia Treatment Centers and Pharmacy Benefit Management

6.5)  Historical review of coagulation factors development

6.5.1)  Factor VIII Concentrates

6.5.2)  Factor IX Concentrates

6.6)  Clinical Development of New Hemophilia Treatments

6.6.1)  Factor VIII

6.6.2)  Factor IX

6.6.3)  Von Willebrand Factor

6.6.4)  Anti-Inhibitor Agents

6.6.5)  Gene Therapy

6.6.6)  Monoclonal Antibodies

6.7)  Factor VIII Market

6.7.1)  Market Development

6.7.2)  Pricing and Reimbursement

6.8)  Factor IX Market

6.9)  Von Willebrand Disease Market

6.9.1)  Historical Developments of VDW treatments

6.10)  Prothrombin Complex Market

6.11)  Inhibitor Market

6.11.1)  Prevalence and Treatment

6.11.2)  Immune Tolerance Induction

6.11.3)  Factor By-Passing Agents: FEIBA NF, Novoseven/Obizur

6.11.4)  Other Inhibitor Treatments

6.11.5)  Market Development

6.12)  Other Bleeding Disorders

6.12.1)  Factor VII

6.12.2)  Factor X

6.12.3)  Factor XI

6.12.4)  Fibrinogen Deficiency

6.12.5)  Factor XIII Deficiency

6.12.6)  Solvent Detergent Plasma

 

7) ALPHA-ONE ANTITRYPSIN MARKET

7.1)  Historical Review

7.2)  Market Development

7.3)  Description and Marketing of Alpha-1 Antitrypsin Products

7.4)  New Indications for Alpha-1 Antitrypsin

7.4.1)  Novel Forms of AAT

7.4.2)  Additional Indications for Alpha-1 Antitrypsin

 

8) C-1 ESTERASE MARKET

8.1)  Market Development of C1-INH

8.2)  Hereditary Angiodema (HAE) Treatment options

8.3)  New Developments of C1 Esterase Inhibitor Therapy

 

9) ANTITHROMBIN III MARKET

9.1)  Market Development of Antithrombin III

9.2)  Historical Development

9.3)  New Developments in Antithrombin III Therapy

 

10) FIBRIN SEALANT MARKET

10.1)  Fibrin Sealant Market

10.1.1)  Market Development

10.1.2)  Historical Development

10.2)  Thrombin Market

10.3)  Other Tissue Sealing Products and Technologies

 

11) OTHER PLASMA PRODUCTS

11.1)  Protein C

 

12) DISTRIBUTION OF PLASMA PRODUCTS

12.1) Distribution channels of Plasma and Recombinant Products

12.1.1) Distribution channels by Product Line

12.1.2) Group Purchase Organizations

12.1.3) Wholesalers and Distributors

12.1.4) Distributors

12.1.5) Wholesalers, Dealers and Distributor s Contact Information

12.2) Specialty Pharmacies/Home Care Companies

 

13)  PROFILES OF THE MAJOR FRACTIONATORS

 

13.1)  APTEVO (EMERGENT BIOSOLUTIONS)

 

13.2)  BIO PRODUCTS LABORATORY (BPL)

 

13.3)  BAYER HEALTHCARE

 

13.4)  BIOTEST BIOPHARMACEUTICALS

 

13.5)  CSL BEHRING

 

13.6)  GRIFOLS USA

 

13.7)  KEDRION BIOPHARMA

 

13.8)  OCTAPHARMA USA

 

13.9)  SHIRE